IMPACT-TB: A Phase II Trial Assessing the Capacity of Low Dose Imatinib to Induce Myelopoiesis and Enhance Host Anti-Microbial Immunity Against Tuberculosis. imatinib Mesylate Per Oral As a Clinical Therapeutic for TB

C. Giver, P. Shaw, H. Fletcher, D. Kaushal, Garcia Pamela,Deborah Omoyege,G. Bisson, T. Gumbo, R. Wallis, E. Waller, D. Kalman

Blood（2019）

Cited 0|Views1

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined

IMPACT-TB*: A Phase II Trial Assessing the Capacity of Low Dose Imatinib to Induce Myelopoiesis and Enhance Host Anti-Microbial Immunity Against Tuberculosis. *imatinib Mesylate Per Oral As a Clinical Therapeutic for TB